BPG is committed to discovery and dissemination of knowledge
Articles in Press
12/5/2025 6:09:54 AM | Browse: 89 | Download: 0
| Category |
Surgery |
| Manuscript Type |
Editorial |
| Article Title |
Total neoadjuvant therapy in rectal cancer: Challenging traditions without compromising surgical safety
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Riya Karmakar, Aditya Kandalkar and Arvind Mukundan |
| Funding Agency and Grant Number |
|
| Corresponding Author |
Arvind Mukundan, Assistant Professor, PhD, Postdoctoral Fellow, School of Engineering and Technology, Sanjivani University, Sanjivani Factory, Singnapur, Kopargaon, Maharashtra 423603, India, Mumbai 621, Mahārāshtra, India. arvindmukund96@gmail.com |
| Key Words |
Total neoadjuvant therapy; Rectal cancer; Chemoradiotherapy; Total mesorectal excision; Rectal Cancer and Preoperative Induction therapy followed by Dedicated Operation trial; FOLFIRINOX; Organ preservation; Surgical safety; Multimodal therapy; Oncology |
| Core Tip |
Total neoadjuvant therapy (TNT) signifies an advancing standard in the treatment of locally advanced rectal cancer, incorporating systemic chemotherapy prior to surgery and radiotherapy. Recent research, including the Rectal Cancer and Preoperative Induction therapy followed by Dedicated Operation based TNT regimen evaluated by Jabbar et al, indicates comparable oncologic safety, comparable oncologic safety and promising postoperative quality-of-life improvements. This editorial synthesizes known data on TNT’s effectiveness, tolerability, and promise for organ preservation, while highlighting ongoing discussions about treatment sequencing, fibrosis risk, and long-term results. The discussion highlights the significance of meticulous patient selection and multidisciplinary supervision in enhancing rectal cancer treatment via personalized, patient-focused multimodal therapy. |
| Citation |
Karmakar R, Kandalkar A, Mukundan A. Total neoadjuvant therapy in rectal cancer: Challenging traditions without compromising surgical safety. World J Gastrointest Oncol 2026; 18(2): 115507 |
 |
Received |
|
2025-10-20 00:36 |
|
Peer-Review Started |
|
2025-10-20 00:36 |
|
First Decision by Editorial Office Director |
|
2025-11-06 08:50 |
|
Return for Revision |
|
2025-11-06 08:50 |
|
Revised |
|
2025-11-12 06:07 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2025-12-05 02:34 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2025-12-05 06:09 |
|
Articles in Press |
|
2025-12-05 06:09 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2026-01-26 15:39 |
| ISSN |
1948-5204 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
© 1993-2026 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
